PMC:7156805 / 5415-5510 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"98","span":{"begin":34,"end":38},"obj":"Gene"}],"attributes":[{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Gene:3565"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T77","span":{"begin":34,"end":36},"obj":"Body_part"}],"attributes":[{"id":"A77","pred":"fma_id","subj":"T77","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":" Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T51","span":{"begin":34,"end":36},"obj":"Chemical"}],"attributes":[{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A52","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":" Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present"}

{"project":"LitCovid-sentences","denotations":[{"id":"T34","span":{"begin":0,"end":95},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present"}